A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy

Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.

In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.